Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pediatrix Medical (MD) Share-based Compensation: 2009-2025

Historic Share-based Compensation for Pediatrix Medical (MD) over the last 17 years, with Q3 2025 value amounting to $3.4 million.

  • Pediatrix Medical's Share-based Compensation rose 3076.92% to $3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.0 million, marking a year-over-year increase of 1421.33%. This contributed to the annual value of $11.9 million for FY2024, which is 369.23% down from last year.
  • Latest data reveals that Pediatrix Medical reported Share-based Compensation of $3.4 million as of Q3 2025, which was up 3076.92% from $2.0 million recorded in Q2 2025.
  • Pediatrix Medical's 5-year Share-based Compensation high stood at $5.8 million for Q2 2021, and its period low was $2.0 million during Q2 2024.
  • In the last 5 years, Pediatrix Medical's Share-based Compensation had a median value of $3.4 million in 2025 and averaged $3.6 million.
  • As far as peak fluctuations go, Pediatrix Medical's Share-based Compensation surged by 3689.25% in 2021, and later crashed by 5918.37% in 2024.
  • Over the past 5 years, Pediatrix Medical's Share-based Compensation (Quarter) stood at $4.0 million in 2021, then decreased by 19.32% to $3.2 million in 2022, then dropped by 6.32% to $3.0 million in 2023, then fell by 9.39% to $2.7 million in 2024, then rose by 24.13% to $3.4 million in 2025.
  • Its Share-based Compensation stands at $3.4 million for Q3 2025, versus $2.0 million for Q2 2025 and $3.6 million for Q1 2025.